Acelyrin

Fresh from IPO, Acelyrin's lead drug fails clinical trial
Fresh from IPO, Acelyrin's lead drug fails clinical trial
Pharmaphorum
Acelyrin
clinical trials
izokibep
hidrad
Flag link:
7 Life Science IPOs in 2023
7 Life Science IPOs in 2023
BioSpace
IPOs
Intensity Therapeutics
Acelyrin
CytoMed Therapeutics
Mineralys Therapeutics
Structure Therapeutics
Genelux
Cadrenal Therapeutics
Flag link:
Biophama's flotation haul creeps higher
Biophama's flotation haul creeps higher
EP Vantage
IPOs
biotech
Acelyrin
Apogee Therapeutics
Azitra
CytoMed Therapeutics
Intensity Therapeutics
Mineralys Therapeutics
Paragon Therapeutics
Sagimet Biosciences
Structure Therapeutics
Turnstone Biologics
Flag link:
Acelyrin makes a splash with IPO, biopharma expects to raise $540M
Acelyrin makes a splash with IPO, biopharma expects to raise $540M
Medical Marketing and Media
Acelyrin
IPOs
Flag link:
Acelyrin follows Kenvue with largest IPO for a biotech startup since 2021
Acelyrin follows Kenvue with largest IPO for a biotech startup since 2021
BioPharma Dive
Acelyrin
IPOs
Kenvue
Flag link:
IPO Market Shows Signs of Life as Acelyrin Begins Nasdaq Bid
IPO Market Shows Signs of Life as Acelyrin Begins Nasdaq Bid
BioSpace
Acelyrin
IPOs
immunology
Flag link:
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
AAD 2023 – UCB and Acelyrin take aim at hidradenitis suppurativa
EP Vantage
AAD
hidradenitis suppurativa
AbbVie
Humira
UCB Pharma
Bimzelx
Acelyrin
izokibep
Flag link:
Acelyrin raises $250M, licenses antibody drug that could rival Novartis, Lilly meds
Acelyrin raises $250M, licenses antibody drug that could rival Novartis, Lilly meds
MedCity News
Acelyrin
Affibody
antibodies
monoclonal antibodies
immunology
Novartis
Eli Lilly
Flag link: